drugset / Trial / NCT07157891
Investigating the Safety and Regenerative Potential of MSC-Derived Secretome Combined With PRGF in Knee Osteoarthritis
Phase 0
Not yet recruiting
25 enrolled
University of the Punjab
Centre of Excellence in Molecular Biology (CEMB), University of the Punjab, Lahore. · collab
RandomizedParallel-groupOpen-labelTreatment
Summary
This Phase I/II randomized clinical trial investigates the safety, feasibility, and early regenerative potential of intra-articular administration of mesenchymal stem cell (MSC)-derived secretome combined with Plasma Rich in Growth Factors (PRGF) in patients with knee osteoarthritis (KOA). The study aims to assess whether this cell-free, biologically enriched therapeutic combination can reduce pain, improve joint function, and promote cartilage repair.
Timeline
- Start
- 2025-12-10
- Primary completion
- 2027-12-11
- Completion
- 2028-12-11
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Plasma Rich in Growth Factors | Other / unclassified | 1 ml | Other |
| Subject | Secretome | Other / unclassified | 2 ml | Other |